NCT04987476Completed
Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)
Hétérogénéité Des Tumeurs Rhabdoides : Approches en " Cellules Uniques " Pour Identifier Des Cibles thérapeutiques
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
The aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 15 (actual)
- First submitted
- 31 Jul 2021
- Start date
- 31 Mar 2022
- Primary completion date
- 21 Feb 2025
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Childhood cancers
- NCT number
- NCT04987476
What you commit to
- Study type: Observational
- Participants enrolled: 15
- From 31 Mar 2022 to the primary completion date, 21 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Aged 0-17 years old
- having a rhabdoid tumor according to clinical and radiological features Or likely having a rhabdoid tumor according to clinical and radiological features
- surgical resection in standard care
- sufficient material for both diagnosis and experimental procedures
- parents' agreement
Age in the registry: - to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.